Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer

Inclusion Criteria:

• Histologically confirmed adenocarcinoma of the prostate
• Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy (after discontinuation of anti-androgen therapy)
• Detectable metastases by bone scan, and/or CT scan, and/or MRI, and/or CXR
• ECOG performance status 0-1

Exclusion Criteria:

• Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer
• History of deep vein thrombosis or pulmonary embolus
• Patients taking anticoagulants (such as coumadin or Heparin). The use of aspirin while on study is acceptable.
• History of a bleeding disorder or recent clinically significant bleeding
• Seropositive for HIV
• History of Hepatitis B, Hepatitis C, or chronic liver disease
• Prior gene therapy or immunotherapy
• Prior chemotherapy for prostate cancer
• Radiation therapy within 4 weeks of the first treatment.
• History of myocardial infarction within 6 months of the first treatment
• History of cerebrovascular accident
• History of previous malignancy, except for the following: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, adequately treated Stage I or II cancer currently in complete remission, or any other cancer that has been in complete remission for at least 5 years
• Evidence of active prostatitis
• Known hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80